Jorveza® (budesonide) is NOW PBS Listed.
Transition your Patient Access Program (PAP) patients onto PBS Jorveza®.
Thank you for participating in the Jorveza® Patient Access Program (PAP) while we waited for the PBS listing.
We hope that the program has helped you become familiar with the use of Jorveza® in the treatment of adult patients with eosinophilic oesophagitis (EoE), but more importantly, that your patients have benefited from this treatment. It has been gratifying to hear from several treating physicians how much Jorveza® has positively impacted patients' quality of life, and that of their families.
As you may be aware, both Jorveza® 1.0 mg and 0.5 mg orally disintegrating tablets are now PBS effective as of 1 May 2022. We had stopped enrolment of new patients into the program at the end of 2021, but continued to provide maintenance therapy for patients as requested by their treating physician on a case-by-case basis. As the PBS listing of Jorveza® provides treatment for both new patients (induction of histologic remission), and continuing treatment or ‘maintenance therapy’, we will now be closing the PAP.
There is provision within the PBS listing to allow the ‘grandfathering’ of any adult EoE patient on a corticosteroid treatment (including those from the PAP receiving Jorveza®) who are in histologic remission (peak eosinophil count of < 5 eos/hpf), to transition to PBS reimbursed Jorveza® which will ensure continuing therapy for these patients.
If you have any questions in this regard, please contact us at admin@drfalkpharma.com.au and we will arrange for your local Dr Falk Pharma representative to contact you.
Thanks again for your participation in the PAP, and your continuing support in the effective treatment of adult patients with EoE.
Yours sincerely,

Stephen Voordouw
Managing Director